摘要
以欧洲药品管理局第一个按照集中审评程序批准的新植物药桦树皮凝胶作为案例,详细介绍了欧盟植物药申请类别及药学和临床研究申报资料要求,从而为我国天然药物研发、技术审评以及审评报告的公开等提供参考。
Episalvan gel is the first new herbal medicinal product approved under the centralized procedure by Europe medicine agency, this article is intended to take it as an example to investigate the application category of herbal medicinal product in Europe as well as its requirements on application dossier of chemistry, manufacturing and controls and clinical trial, with the aim of providing reference to the research & development, technical review and public assessment reports of natural medicinal product in China.
作者
关宏峰
刘炳林
GUAN Hong-feng;LIU Bing-lin(Center for Drug Evaluation National Medical Products Administration,Bejing 100022,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2021年第4期490-496,共7页
The Chinese Journal of Clinical Pharmacology
关键词
欧洲药品管理局
新植物药
桦树皮凝胶
审评思路
审评报告公开
European Medicines Agency
new herbal medicinal product
Episalvan gel
assessment consideration
public assessment reports